Sylvester Comprehensive Cancer Center

  • 20230725 - Correa Zelia

  • Investigator:
    Zelia Correa
    RCname Email

    Coordinator:

    IRB: 20230725

    SDG: Cutaneous and Ocular Malignancies
    Disease Site(s):

    Eye and Orbit

    Sponsor: Ideaya Biosciences

    Enrolling Sites:

    ABLEH
    Aventura
    Deerfield
    Gables
    Sylvester

    Title:

    (Neo)adjuvant IDE196 (darovasertib) in patients with localized ocular melanoma

    Eligibility Criteria - NCT05907954 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231156 - Crystal Jessica

  • Investigator:
    Jessica Crystal
    RCname Email

    Coordinator:

    IRB: 20231156

    SDG: Cutaneous and Ocular Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: SWOG

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    MELANOMA MARGINS TRIAL (MELMART): A PHASE III, MULTI-CENTRE, MULTI-NATIONAL RANDOMISED CONTROL TRIAL INVESTIGATING 1CM V 2CM WIDE EXCISION MARGINS FOR PRIMARY CUTANEOUS MELANOMA

    Eligibility Criteria - NCT03860883 *This information has been extracted from " www.clinicaltrials.gov"

  • ECOG EA6141 - Feun, Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:
    RCemailImg Milton Ortega
    RCphone +1 (305) 2432086

    IRB: 20150909

    SDG: Cutaneous and Ocular Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: ECOG

    Enrolling Sites:

    Aventura
    Deerfield
    Plantation
    Sylvester

    Title:

    Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

    Eligibility Criteria - NCT02339571 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201288 - Feun Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:

    IRB: 20201288

    SDG: Cutaneous and Ocular Malignancies
    Disease Site(s):

    Multiple

    Sponsor: ECOG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)

    Eligibility Criteria - NCT04462406 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Hernandez Aya, Leonel

  • Investigator:
    Leonel Hernandez Aya
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone +1 (786) 5828551

    IRB: 20180802

    SDG: Cutaneous and Ocular Malignancies
    Disease Site(s):

    Bladder,Breast-Female,Colon,Melanoma, skin,Other Skin

    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester

    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211228 - Hernandez Aya Leonel

  • Investigator:
    Leonel Hernandez Aya
    RCname Email

    Coordinator:
    RCemailImg Edda Bisbal-Loubriel
    RCphone +1 (305) 2430326

    IRB: 20211228

    SDG: Cutaneous and Ocular Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: Syntrix Pharmaceuticals

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

    Eligibility Criteria - NCT03161431 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220869 - Hernandez Aya Leonel

  • Investigator:
    Leonel Hernandez Aya
    RCname Email

    Coordinator:

    IRB: 20220869

    SDG: Cutaneous and Ocular Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: ETCTN

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    Phase 1/2 Study of an EZH2 inhibitor (tazemetostat) in combination with dual BRAF/MEK inhibition in patients with BRAF- mutated metastatic melanoma who progressed on prior BRAF/MEK inhibitor therapy

    Eligibility Criteria - NCT04557956 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230131 - Hernandez Aya Leonel

  • Investigator:
    Leonel Hernandez Aya
    RCname Email

    Coordinator:

    IRB: 20230131

    SDG: Cutaneous and Ocular Malignancies
    Disease Site(s):

    Multiple

    Sponsor: Alliance

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    A Randomized Phase II Trial of Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Mucosal Melanoma

    Eligibility Criteria - NCT05111574 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230532 - Hernandez Aya Leonel

  • Investigator:
    Leonel Hernandez Aya
    RCname Email

    Coordinator:

    IRB: 20230532

    SDG: Cutaneous and Ocular Malignancies
    Disease Site(s):

    Multiple

    Sponsor: Asher Biotherapeutics

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester
    UMH

    Title:

    An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

    Eligibility Criteria - NCT05653882 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230072 - Kirsner Robert

  • Investigator:
    Robert Kirsner
    RCname Email

    Coordinator:

    IRB: 20230072

    SDG: Cutaneous and Ocular Malignancies
    Disease Site(s):

    Multiple

    Sponsor: Hoth Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors

    Eligibility Criteria - NCT05639933 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230966 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:

    IRB: 20230966

    SDG: Cutaneous and Ocular Malignancies
    Disease Site(s):

    Eye and Orbit

    Sponsor: Ideaya Biosciences

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    IDE196 (Darovasertib) In Combination With Crizotinib Versus Investigators Choice Of Treatment As First-Line Therapy In HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)

    Eligibility Criteria - NCT05987332 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231406 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    Coordinator:

    IRB: 20231406

    SDG: Cutaneous and Ocular Malignancies
    Disease Site(s):

    Kidney

    Sponsor: ETCTN

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancer

    Eligibility Criteria - NCT05896839 *This information has been extracted from " www.clinicaltrials.gov"